Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib)

K. Banovac, J. M. Williams, L. D. Patrick, Allan D Levi

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Study design: A randomized, prospective, double-blind, placebo-controlled clinical trial. Objectives: To determine the effect of COX-2-selective inhibitor on the prevention of heterotopic ossification (HO) after spinal cord injury (SCI). Setting: County and University Teaching Hospital, Miami, FL, USA. Methods: A total of 76 patients were enrolled in the study. Among them, 39 patients received placebo, and 37 received COX-2-selective inhibitor rofecoxib 25 mg daily for a period of 4 weeks. Prevention was started 3 weeks after spinal cord injury (SCI). In both groups of patients there was similar age as well as the level of SCI and ASIA impairment scale. Two methods were used to diagnose early HO, clinical symptoms and bone scintigraphy. Radiography was used for diagnosis of late stages of HO development. Results: A significantly lower incidence of HO was found in the rofecoxib group (13.4%) than in the placebo group (33.3%: P<0.05). In patients receiving rofecoxib, there was a 2.5 times lower relative risk of developing HO than in the placebo group (95% CI, 2.3-6). There were no patients who discontinued the study due to adverse effects of medication. Conclusion: Our data suggest that COX-2-selective inhibitor rofecoxib is an effective medication in prevention of HO after SCI.

Original languageEnglish
Pages (from-to)707-710
Number of pages4
JournalSpinal Cord
Volume42
Issue number12
DOIs
StatePublished - Dec 1 2004

Fingerprint

Heterotopic Ossification
Cyclooxygenase 2 Inhibitors
Spinal Cord Injuries
Placebos
Delayed Diagnosis
Controlled Clinical Trials
Radiography
Teaching Hospitals
Radionuclide Imaging
rofecoxib
Bone and Bones
Incidence

Keywords

  • COX-2-selective inhibitor
  • Heterotopic ossification
  • Prevention
  • Rofecoxib
  • Spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). / Banovac, K.; Williams, J. M.; Patrick, L. D.; Levi, Allan D.

In: Spinal Cord, Vol. 42, No. 12, 01.12.2004, p. 707-710.

Research output: Contribution to journalArticle

Banovac, K. ; Williams, J. M. ; Patrick, L. D. ; Levi, Allan D. / Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). In: Spinal Cord. 2004 ; Vol. 42, No. 12. pp. 707-710.
@article{6ec757d65135420d9e986f9fab3fe2e0,
title = "Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib)",
abstract = "Study design: A randomized, prospective, double-blind, placebo-controlled clinical trial. Objectives: To determine the effect of COX-2-selective inhibitor on the prevention of heterotopic ossification (HO) after spinal cord injury (SCI). Setting: County and University Teaching Hospital, Miami, FL, USA. Methods: A total of 76 patients were enrolled in the study. Among them, 39 patients received placebo, and 37 received COX-2-selective inhibitor rofecoxib 25 mg daily for a period of 4 weeks. Prevention was started 3 weeks after spinal cord injury (SCI). In both groups of patients there was similar age as well as the level of SCI and ASIA impairment scale. Two methods were used to diagnose early HO, clinical symptoms and bone scintigraphy. Radiography was used for diagnosis of late stages of HO development. Results: A significantly lower incidence of HO was found in the rofecoxib group (13.4{\%}) than in the placebo group (33.3{\%}: P<0.05). In patients receiving rofecoxib, there was a 2.5 times lower relative risk of developing HO than in the placebo group (95{\%} CI, 2.3-6). There were no patients who discontinued the study due to adverse effects of medication. Conclusion: Our data suggest that COX-2-selective inhibitor rofecoxib is an effective medication in prevention of HO after SCI.",
keywords = "COX-2-selective inhibitor, Heterotopic ossification, Prevention, Rofecoxib, Spinal cord injury",
author = "K. Banovac and Williams, {J. M.} and Patrick, {L. D.} and Levi, {Allan D}",
year = "2004",
month = "12",
day = "1",
doi = "10.1038/sj.sc.3101628",
language = "English",
volume = "42",
pages = "707--710",
journal = "Spinal Cord",
issn = "1362-4393",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib)

AU - Banovac, K.

AU - Williams, J. M.

AU - Patrick, L. D.

AU - Levi, Allan D

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Study design: A randomized, prospective, double-blind, placebo-controlled clinical trial. Objectives: To determine the effect of COX-2-selective inhibitor on the prevention of heterotopic ossification (HO) after spinal cord injury (SCI). Setting: County and University Teaching Hospital, Miami, FL, USA. Methods: A total of 76 patients were enrolled in the study. Among them, 39 patients received placebo, and 37 received COX-2-selective inhibitor rofecoxib 25 mg daily for a period of 4 weeks. Prevention was started 3 weeks after spinal cord injury (SCI). In both groups of patients there was similar age as well as the level of SCI and ASIA impairment scale. Two methods were used to diagnose early HO, clinical symptoms and bone scintigraphy. Radiography was used for diagnosis of late stages of HO development. Results: A significantly lower incidence of HO was found in the rofecoxib group (13.4%) than in the placebo group (33.3%: P<0.05). In patients receiving rofecoxib, there was a 2.5 times lower relative risk of developing HO than in the placebo group (95% CI, 2.3-6). There were no patients who discontinued the study due to adverse effects of medication. Conclusion: Our data suggest that COX-2-selective inhibitor rofecoxib is an effective medication in prevention of HO after SCI.

AB - Study design: A randomized, prospective, double-blind, placebo-controlled clinical trial. Objectives: To determine the effect of COX-2-selective inhibitor on the prevention of heterotopic ossification (HO) after spinal cord injury (SCI). Setting: County and University Teaching Hospital, Miami, FL, USA. Methods: A total of 76 patients were enrolled in the study. Among them, 39 patients received placebo, and 37 received COX-2-selective inhibitor rofecoxib 25 mg daily for a period of 4 weeks. Prevention was started 3 weeks after spinal cord injury (SCI). In both groups of patients there was similar age as well as the level of SCI and ASIA impairment scale. Two methods were used to diagnose early HO, clinical symptoms and bone scintigraphy. Radiography was used for diagnosis of late stages of HO development. Results: A significantly lower incidence of HO was found in the rofecoxib group (13.4%) than in the placebo group (33.3%: P<0.05). In patients receiving rofecoxib, there was a 2.5 times lower relative risk of developing HO than in the placebo group (95% CI, 2.3-6). There were no patients who discontinued the study due to adverse effects of medication. Conclusion: Our data suggest that COX-2-selective inhibitor rofecoxib is an effective medication in prevention of HO after SCI.

KW - COX-2-selective inhibitor

KW - Heterotopic ossification

KW - Prevention

KW - Rofecoxib

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=11244296166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244296166&partnerID=8YFLogxK

U2 - 10.1038/sj.sc.3101628

DO - 10.1038/sj.sc.3101628

M3 - Article

C2 - 15179440

AN - SCOPUS:11244296166

VL - 42

SP - 707

EP - 710

JO - Spinal Cord

JF - Spinal Cord

SN - 1362-4393

IS - 12

ER -